Company news from the 05/08/07 News Brief

Share this article:
E-Healthcare Solutions (EHS) announced that Ascend Media Healthcare has signed an exclusive representation agreement that names EHS as the sole provider of on-line advertising for Ascend Media’s Healthcare portfolio of medical and healthcare websites. The agreement calls for EHS to centrally sell and deliver advertising campaigns to the online publications in the healthcare division, including Cardiology Review, The American Journal of Managed Care, Pharmacy Times, Internal Medicine World Report, Physician’s Money Digest, Surgical Rounds, Family Practice Recertification and Resident & Staff Physician. Bayer HealthCare Pharmaceuticals , a US-based pharmaceuticals unit of Bayer HealthCare, and Intendis , a US-based affiliate of Bayer Schering Pharma AG, Germany, announced that they will jointly promote Yaz (drospirenone/ethinyl estradiol) as a treatment for moderate acne in women who desire an oral contraceptive for birth control. The agreement went into effect on May 1, as part of an overall strategy to introduce dermatologists to the anti-acne benefits of Yaz. Investigators will present new clinical data demonstrating the efficacy of Yaz in the treatment of moderate acne at the American College of Obstetricians and Gynecologists (ACOG) annual clinical meeting in San Diego. Yaz is the only oral contraceptive approved for the treatment of premenstrual dysphoric disorder (PMDD) in women who desire an oral contraceptive for birth control. PMDD is a condition in which women's premenstrual symptoms are severe enough to impact activities, work or relationships. In January, 2007, Yaz received FDA approval as a treatment for moderate acne in women who desire an oral contraceptive for birth control.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union